Cargando…
Mixed dementia: A review of the evidence
Mixed dementia is the coexistence of Alzheimer's disease and cerebrovascular disease (CVD) in the same demented patient. Currently, its diagnosis and treatment remains a challenge for practitioners. To provide an overview of the epidemiology, pathogenesis, natural history, diagnosis, and therap...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação de Neurologia Cognitiva e do Comportamento
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769994/ https://www.ncbi.nlm.nih.gov/pubmed/29354216 http://dx.doi.org/10.1590/1980-57642016dn11-040005 |
_version_ | 1783293000514797568 |
---|---|
author | Custodio, Nilton Montesinos, Rosa Lira, David Herrera-Pérez, Eder Bardales, Yadira Valeriano-Lorenzo, Lucía |
author_facet | Custodio, Nilton Montesinos, Rosa Lira, David Herrera-Pérez, Eder Bardales, Yadira Valeriano-Lorenzo, Lucía |
author_sort | Custodio, Nilton |
collection | PubMed |
description | Mixed dementia is the coexistence of Alzheimer's disease and cerebrovascular disease (CVD) in the same demented patient. Currently, its diagnosis and treatment remains a challenge for practitioners. To provide an overview of the epidemiology, pathogenesis, natural history, diagnosis, and therapy of Mixed Vascular-Alzheimer Dementia (MVAD). The literature was reviewed for articles published between 1990-2016 by using the keywords linked to MVAD. Neuropathological studies indicate that MVAD is a very common pathological finding in the elderly with a prevalence about of 22%. The distinction between Alzheimer's dementia and vascular dementia (VD) is complex because their clinical presentation can overlap. There are international criteria for the MVAD diagnosis. The pharmacologic therapy shows modest clinical benefits that are similar among all drugs used in patients with Alzheimer's dementia and VD. The non-pharmacologic therapy includes the rigorous management of cardiovascular risk factors (especially hypertension) and the promotion of a healthy diet. The diagnosis and treatment of MVAD cannot be improved without further studies. Currently available medications provide only modest clinical benefits once a patient has developed MVAD. In subjects at risk, the antihypertensive therapy and healthy diet should be recommend for preventing or slowing the progression of MVAD. |
format | Online Article Text |
id | pubmed-5769994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Associação de Neurologia Cognitiva e do Comportamento |
record_format | MEDLINE/PubMed |
spelling | pubmed-57699942018-01-19 Mixed dementia: A review of the evidence Custodio, Nilton Montesinos, Rosa Lira, David Herrera-Pérez, Eder Bardales, Yadira Valeriano-Lorenzo, Lucía Dement Neuropsychol Views & Reviews Mixed dementia is the coexistence of Alzheimer's disease and cerebrovascular disease (CVD) in the same demented patient. Currently, its diagnosis and treatment remains a challenge for practitioners. To provide an overview of the epidemiology, pathogenesis, natural history, diagnosis, and therapy of Mixed Vascular-Alzheimer Dementia (MVAD). The literature was reviewed for articles published between 1990-2016 by using the keywords linked to MVAD. Neuropathological studies indicate that MVAD is a very common pathological finding in the elderly with a prevalence about of 22%. The distinction between Alzheimer's dementia and vascular dementia (VD) is complex because their clinical presentation can overlap. There are international criteria for the MVAD diagnosis. The pharmacologic therapy shows modest clinical benefits that are similar among all drugs used in patients with Alzheimer's dementia and VD. The non-pharmacologic therapy includes the rigorous management of cardiovascular risk factors (especially hypertension) and the promotion of a healthy diet. The diagnosis and treatment of MVAD cannot be improved without further studies. Currently available medications provide only modest clinical benefits once a patient has developed MVAD. In subjects at risk, the antihypertensive therapy and healthy diet should be recommend for preventing or slowing the progression of MVAD. Associação de Neurologia Cognitiva e do Comportamento 2017 /pmc/articles/PMC5769994/ /pubmed/29354216 http://dx.doi.org/10.1590/1980-57642016dn11-040005 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Views & Reviews Custodio, Nilton Montesinos, Rosa Lira, David Herrera-Pérez, Eder Bardales, Yadira Valeriano-Lorenzo, Lucía Mixed dementia: A review of the evidence |
title | Mixed dementia: A review of the evidence |
title_full | Mixed dementia: A review of the evidence |
title_fullStr | Mixed dementia: A review of the evidence |
title_full_unstemmed | Mixed dementia: A review of the evidence |
title_short | Mixed dementia: A review of the evidence |
title_sort | mixed dementia: a review of the evidence |
topic | Views & Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769994/ https://www.ncbi.nlm.nih.gov/pubmed/29354216 http://dx.doi.org/10.1590/1980-57642016dn11-040005 |
work_keys_str_mv | AT custodionilton mixeddementiaareviewoftheevidence AT montesinosrosa mixeddementiaareviewoftheevidence AT liradavid mixeddementiaareviewoftheevidence AT herreraperezeder mixeddementiaareviewoftheevidence AT bardalesyadira mixeddementiaareviewoftheevidence AT valerianolorenzolucia mixeddementiaareviewoftheevidence |